# Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

> **NCT05468359** · PHASE1,PHASE2 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 64 (estimated)

## Conditions studied

- Refractory Solid Tumor
- Hepatocellular Carcinoma
- Malignant Solid Tumor
- Pediatric Cancer
- Pediatric Solid Tumor
- Fibrolamellar Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Sorafenib
- **DRUG:** Bevacizumab
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05468359
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-07
- **Primary completion:** 2032-06
- **Final completion:** 2037-06
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468359, "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05468359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*